Research
Hormonal
Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight.
Practitioners may consider GLP-1 agonists and incretin multi-agonists as effective options for weight management in obese patients.
StrongSupportsmedium confidence
Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight among hypoglycemic drugs in a number of pilot and larger studies.
Why this rating
Based on the mention of pilot and larger studies indicating significant efficacy.
Source
Possibilities of using glucagon-like peptide-1 agonists and incretin multi-agonists in pharmacotherapy of obesity and metabolic syndrome
Vadim V. Abramov et al. · Glavvrač (Chief Medical Officer) · 2024
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →